BD9 is a multibody that targets IL-13 and TSLP, and has potential to treat TH-2-driven inflammatory diseasesBD9 designed using Biolojic’s Multibody Platform, which generates Antibodies capable of addr ...

a dual-specific multibody targeting both TSLP (Thymic stromal lymphopoietin) and IL-13. Teva has an exclusive license to develop BD9 for the treatment of TH2-driven inflammatory diseases such as ...

(“Biolojic”), a biotechnology company using computational biology and artificial intelligence to design next generation, multifunctional antibodies known as multibodies, announced today that Teva ...

TEVA starts IND-enabling studies for BD9, a dual-targeting multibody for asthma and eczema. Shares rise on the news.

Register now for this upcoming webinar, hosted by multiphysics simulation software provider COMSOL, exploring how to model and simulate multibody dynamics. Multibody dynamics modelling enables ...

Adams2Actran is an automated Interface to connect an acoustics simulation performed with Actran to the Multibody Dynamics (MBD) solution of Adams. As a follow-up of the transient dynamics analysis ...

Developed by the University of Western Australia's Marine Energy Research Australia knowledge hub, the device is called the Moored MultiMode Multibody (M4) Wave Energy Demonstration Project.